Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease

References

• Akinyemi AJ, Oboh G, Fadaka AO, et al. (2017). Curcumin administration suppress acetylcholinesterase gene expression in cadmium treated rats. Neurotoxicology 62:75–9.
   PubMed Web of Science ®Google Scholar
• Amin FU, Shah SA, Badshah H, et al. (2017). Anthocyanins encapsulated by PLGA@PEG nanoparticles potentially improved its free radical scavenging capabilities via p38/JNK pathway against Abeta1-42-induced oxidative stress. J Nanobiotechnol 15:12.
   PubMed Web of Science ®Google Scholar
• Anitha A, Deepagan VG, Divya Rani VV, et al. (2011). Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles. Carbohydr Polym 84:1158–64.
   Web of Science ®Google Scholar
• Arendt T. (2009). Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118:167–79.
   PubMed Web of Science ®Google Scholar
• Bloom GS. (2014). Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505–8.
   PubMed Web of Science ®Google Scholar
• Chen F, Ghosh A, Wu F, et al. (2017). Preventive effect of genetic knockdown and pharmacological blockade of CysLT1R on lipopolysaccharide (LPS)-induced memory deficit and neurotoxicity in vivo. Brain Behav Immun 60:255–69.
   PubMed Web of Science ®Google Scholar
• Chen X, Zou LQ, Niu J, et al. (2015). The stability, sustained release and cellular antioxidant activity of curcumin nanoliposomes. Molecules 20:14293–311.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Doody R, Clark C. (2007). Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 69:1622–34.
   PubMed Web of Science ®Google Scholar
• Davis SA, Gan KA, Dowell JA, et al. (2017). TDP-43 expression influences amyloid beta plaque deposition and tau aggregation. Neurobiol Dis 103:154–62.
   PubMed Web of Science ®Google Scholar
• Fan S, Zhang B, Luan P, et al. (2015). PI3K/AKT/mTOR/p70S6K pathway is involved in Aβ25-35-induced autophagy. BioMed Res Int 2015:161020.
   PubMed Web of Science ®Google Scholar
• Feng HL, Dang HZ, Fan H, et al. (2016). Curcumin ameliorates insulin signalling pathway in brain of Alzheimer's disease transgenic mice. Int J Immunopathol Pharmacol 29:734–41.
   PubMed Web of Science ®Google Scholar
• Fredenberg S, Wahlgren M, Reslow M, Axelsson A. (2011). The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-a review. Int J Pharm 415:34–52.
   PubMed Web of Science ®Google Scholar
• Ganugula R, Arora M, Jaisamut P, et al. (2017). Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus. Br J Pharmacol. 174:2074–84.
   PubMed Web of Science ®Google Scholar
• Gong B, Cao Z, Zheng P, et al. (2006). Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126:775–88.
   PubMed Web of Science ®Google Scholar
• Goozee KG, Shah TM, Sohrabi HR, et al. (2016). Examining the potential clinical value of Cur in the prevention and diagnosis of Alzheimer's disease. Br J Nutr 115:449–65.
   PubMed Web of Science ®Google Scholar
• Guglielmotto M, Monteleone D, Giliberto L, et al. (2011). Amyloid-β(4)(2) activates the expression of BACE1 through the JNK pathway. J Alzheimers Dis 27:871–83.
   PubMed Web of Science ®Google Scholar
• Hamaguchi T, Ono K, Yamada M. (2010). Review: Curcumin and Alzheimer's disease. CNS Neurosci Ther 16:285–97.
   PubMed Web of Science ®Google Scholar
• Huang HC, Chang P, Dai XL, Jiang ZF. (2012). Protective effects of curcumin on amyloid-beta-induced neuronal oxidative damage. Neurochem Res 37:1584–97.
   PubMed Web of Science ®Google Scholar
• Huang HC, Tang D, Xu K, Jiang ZF. (2014). Curcumin attenuates amyloid-beta-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3beta signaling pathway. J Recept Signal Transduct Res 34:26–37.
   PubMed Web of Science ®Google Scholar
• Jain KK. (2012). Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond) 7:1225–33.
   PubMed Web of Science ®Google Scholar
• Jain RA. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475–90.
   PubMed Web of Science ®Google Scholar
• Jankowsky JL, Fadale DJ, Anderson J, et al. (2004). Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Gen 13:159–70.
   PubMed Web of Science ®Google Scholar
• Jiao SS, Yao XQ, Liu YH, et al. (2015). Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits. Proc Natl Acad Sci USA 112:5225–30.
   PubMed Web of Science ®Google Scholar
• Jin WS, Shen LL, Bu XL, et al. (2017). Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathol 134:207–20.
   PubMed Web of Science ®Google Scholar
• Jucker M, Walker LC. (2015). Neurodegeneration: amyloid-β pathology induced in humans. Nature 525:193–4.
   PubMed Web of Science ®Google Scholar
• Khalil NM, do Nascimento TC, Casa DM, et al. (2013). Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 101:353–60.
   PubMed Web of Science ®Google Scholar
• Li J, Feng L, Fan L, et al. (2011). Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32:4943–50.
   PubMed Web of Science ®Google Scholar
• Liu J, Xu L, Liu C, et al. (2012). Preparation and characterization of cationic curcumin nanoparticles for improvement of cellular uptake. Carbohydr Polym 90:16–22.
   PubMed Web of Science ®Google Scholar
• Liu X, Mo Y, Guo R, et al. (2016). Synthesis, characterisation and preliminary investigation of the haemocompatibility of polyethyleneimine-grafted carboxymethyl chitosan for gene delivery. Mater Sci Eng C Mater Biol Appl 62:173–82.
   PubMed Web of Science ®Google Scholar
• Liu Z, Gao X, Kang T, et al. (2013). B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjugate Chem 24:997–1007.
   PubMed Web of Science ®Google Scholar
• Manju S, Sreenivasan K. (2011). Hollow microcapsules built by layer by layer assembly for the encapsulation and sustained release of curcumin. Colloids Surf B Biointerfaces 82:588–93.
   PubMed Web of Science ®Google Scholar
• Mathew A, Fukuda T, Nagaoka Y, et al. (2012). Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PloS One 7:e32616.
   PubMed Web of Science ®Google Scholar
• Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. (2014). Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials 35:3365–83.
   PubMed Web of Science ®Google Scholar
• Ngo ST, Li MS. (2012). Cur binds to Abeta1-40 peptides and fibrils stronger than ibuprofen and naproxen. J Phys Chem B 116:10165–75.
   PubMed Web of Science ®Google Scholar
• Nie Y, Schaffert D, Rodl W, et al. (2011). Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy. J Control Release 152:127–34.
   PubMed Web of Science ®Google Scholar
• Oddo S, Caccamo A, Shepherd JD, et al. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–21.
   PubMed Web of Science ®Google Scholar
• Paka GD, Ramassamy C. (2017). Optimization of curcumin-loaded PEG-PLGA nanoparticles by GSH functionalization: investigation of the internalization pathway in neuronal cells. Mol Pharmaceutics 14:93–106.
   PubMed Web of Science ®Google Scholar
• Pandey PK, Sharma AK, Gupta U. (2016). Blood brain barrier: an overview on strategies in drug delivery, realistic in vitro modeling and in vivo live tracking. Tissue Barriers 4:e1129476.
   PubMed Web of Science ®Google Scholar
• Perez-Gonzalez R, Pascual C, Antequera D, et al. (2013). Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol Aging 34:2133–45.
   PubMed Web of Science ®Google Scholar
• Perrone D, Ardito F, Giannatempo G, et al. (2015). Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med 10:1615–23.
   PubMed Web of Science ®Google Scholar
• Prades R, Guerrero S, Araya E, et al. (2012). Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials 33:7194–205.
   PubMed Web of Science ®Google Scholar
• Prince M, Wimo A, Guerchet M, et al. (2015). World Alzheimer Report 2015- The global impact of dementia. Alzheimer’s Disease International. Available at: http://www.worldalzreport2015.org
   Google Scholar
• Puzzo D, Gulisano W, Palmeri A, Arancio O. (2015). Rodent models for Alzheimer's disease drug discovery. Expert Opin Drug Discov 10:703–11.
   PubMed Web of Science ®Google Scholar
• Roberson ED, Scearce-Levie K, Palop JJ, et al. (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316:750–4.
   PubMed Web of Science ®Google Scholar
• Sanabria-Castro A, Alvarado-Echeverria I, Monge-Bonilla C. (2017). Molecular pathogenesis of Alzheimer's disease: an update. Ann Neurosci 24:46–54.
   PubMed Web of Science ®Google Scholar
• Scheltens P, Blennow K, Breteler MMB, et al. (2016). Alzheimer's disease. Lancet 388:505–17.
   PubMed Web of Science ®Google Scholar
• Schwab C, Hosokawa M, McGeer PL. (2004). Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 188:52–64.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192:106–13.
   PubMed Web of Science ®Google Scholar
• Shaikh J, Ankola DD, Beniwal V, et al. (2009). Nanoparticle encapsulation improves oral bioavailability of Cur by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sc 37:223–30.
   PubMed Web of Science ®Google Scholar
• Song Z, Feng R, Sun M, et al. (2011). Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 354:116–23
   PubMed Web of Science ®Google Scholar
• Stanic Z. (2017). Curcumin, a compound from natural sources, a true scientific challenge - a review. Plant Foods Hum Nutr 72:1–12.
   PubMed Web of Science ®Google Scholar
• Tang M, Taghibiglou C. (2017). The mechanisms of action of Curcumin in Alzheimer's disease. J Alzheimers Dis 58:1003–16.
   PubMed Web of Science ®Google Scholar
• Urnauer S, Klutz K, Grunwald GK, et al. (2017). Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes. J Gene Med 19. doi: 10.1002/jgm.2957
   PubMed Web of Science ®Google Scholar
• van Rooy I, Mastrobattista E, Storm G, et al. (2011). Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release 150:30–6.
   PubMed Web of Science ®Google Scholar
• Visser CC, Stevanovic S, Heleen Voorwinden L, et al. (2004). Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target 12:145–50.
   PubMed Web of Science ®Google Scholar
• Xia H, Anderson B, Mao Q, Davidson BL. (2000). Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 74:11359–66.
   PubMed Web of Science ®Google Scholar
• Xiao S, Zhou D, Luan P, et al. (2016). Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability. Biomaterials 106:98–110.
   PubMed Web of Science ®Google Scholar
• Yan R. (2017). Physiological functions of the beta-site amyloid precursor protein cleaving enzyme 1 and 2. Front Mol Neurosci 10:97.
   PubMed Web of Science ®Google Scholar
• Yin T, Yang L, Liu Y, et al. (2015). Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease. Acta Biomater 25:172–83.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shen C, Chu J, et al. (2014). Icariin decreases the expression of APP and BACE-1 and reduces the beta-amyloid burden in an APP transgenic mouse model of Alzheimer's disease. Int J Biol Sci 10:181–91.
   PubMed Web of Science ®Google Scholar
• Zhao L, Du J, Duan Y, et al. (2012). Curcumin loaded mixed micelles composed of Pluronic P123 and F68: preparation, optimization and in vitro characterization. Colloids Surf B Biointerfaces 97:101–8.
   PubMed Web of Science ®Google Scholar
• Zheng K, Dai X, Xiao N, et al. (2017). Curcumin ameliorates memory decline via inhibiting BACE1 expression and beta-amyloid pathology in 5xFAD transgenic mice. Mol Neurobiol 54:1967–77.
   PubMed Web of Science ®Google Scholar